NGS‐based liquid biopsy profiling identifies mechanisms of resistance to ALK inhibitors: a step toward personalized NSCLC treatment

Despite impressive and durable responses, nonsmall cell lung cancer (NSCLC) patients treated with anaplastic lymphoma kinase (ALK) inhibitors (ALK‐Is) ultimately progress due to development of resistance. Here, we have evaluated the clinical utility of circulating tumor DNA (ctDNA) profiling by next...

Descripción completa

Detalles Bibliográficos
Autores principales: Sánchez‐Herrero, Estela, Serna‐Blasco, Roberto, Ivanchuk, Vadym, García‐Campelo, Rosario, Dómine Gómez, Manuel, Sánchez, José M., Massutí, Bartomeu, Reguart, Noemi, Camps, Carlos, Sanz‐Moreno, Sandra, Calabuig‐Fariñas, Silvia, Jantus‐Lewintre, Eloísa, Arnal, Magdalena, Fernández‐Orth, Dietmar, Calvo, Virginia, González‐Rumayor, Víctor, Provencio, Mariano, Romero, Atocha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8410554/
https://www.ncbi.nlm.nih.gov/pubmed/34058070
http://dx.doi.org/10.1002/1878-0261.13033

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8410554/
https://www.ncbi.nlm.nih.gov/pubmed/34058070
http://dx.doi.org/10.1002/1878-0261.13033

Ejemplares similares